The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Bi-specific antibodies in HER2+ gastric cancer

Name: Bi-specific antibodies in HER2+ gastric cancer
Uploaded: 2021-01-13T00:00:00Z
Duration: 1 min 13 s
Description: Hyun C. Chung, MD, PhD, Yonsei Cancer Center, Seoul, Republic of Korea, provides an overview of ongoing studies in patients with HER2+ gastric cancer, including the use of novel immunotherapy and bi-specific antibodies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Hyun C. Chung • 13 Jan 2021

ASCO GI 2021

Gastric Cancer Gastrointestinal Cancer Antibodies

Hyun C. Chung, MD, PhD, Yonsei Cancer Center, Seoul, Republic of Korea, provides an overview of ongoing studies in patients with HER2+ gastric cancer, including the use of novel immunotherapy and bi-specific antibodies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).